Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.

Jul 23, 2024 · Osimertinib is approved for use as adjuvant therapy for patients with completely resected stage IB-IIIA NSCLC harboring an EGFR exon 19 deletion or exon 21 L858R mutation, on the basis of the PFS and OS benefits noted in the phase III randomized ADAURA trial. 4 To our knowledge, the LAURA trial is the first randomized trial to identify a PFS benefit with consolidation EGFR-targeted therapy ...

Sep 15, 2020 · Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation (P < .01) between subgroups.Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3 ...

Nov 5, 2024 · Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial

Why Publish With JCO Journals. Impact and Reach: With over 18 million article views and 10 million unique visitors, the JCO Journals ensure that practice-changing research gets in the hands of people who need it most. JCO Journals received over 190,000 citations in 2022. EZSubmit: JCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for ...

There were approximately 725,000 new cases and 664,000 deaths worldwide due to hepatocellular carcinoma (HCC) in 2020. HCC comprises 75%-85% of primary liver cancer cases and is the fourth-leading cause of annual cancer deaths worldwide. 1 In the United States, it is estimated that liver cancer will account for approximately 41,210 new cases and about 29,380 deaths in 2023. 2 Risk factors vary ...

Jul 13, 2020 · The systematic reviews included 3 publications from the updated search and 10 publications on CPIs. Two phase III trials in adult patients with non–small-cell lung cancers evaluating a platinum-based doublet with or without the programmed death 1 (PD-1) inhibitor pembrolizumab recommended that all patients receive dexamethasone as a component of the prophylactic antiemetic regimen.

Feb 3, 2020 · As well described in the clinical review by Brown and Gupta 1 in this issue of JCO Oncology Practice, oral mucositis is a common toxicity of cancer therapy.The morbidity of oral mucositis includes pain, nutritional compromise, and infection risk, which potentially result in breaks or dose reductions in cancer therapy.

Jan 10, 2024 · Clinicians should recommend treatment according to menopausal status, pathological and biomarker features when quality results are available. In first-line, for hormone receptor (HR)–positive MBC, when a non-steroidal aromatase inhibitor and CDK 4/6 inhibitor combination is unavailable, use hormonal therapy alone.

Immunotherapy has revolutionized the treatment of many different types of cancers. Immune checkpoint inhibitors (ICPis) targeting cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) work by preventing the receptors and ligands from binding to each other, thereby disrupting signaling so that T cells can recognize and attack cancer ...